Baicalin
description1
description2
Basic information
Product Name: Baicalin
IUPAC Name: (3β,6α,16β,20R,24S)-20,24-Epoxy-3-(β-D-xylopyranosyloxy)-16,25-dihydroxy-9,19-cyclolanostane-6-yl β-D-glucopyranoside
CAS No.: 21967-41-9
Molecular Formula: C₄₁H₆₈O₁₄
Physicochemical Properties:
Parameter |
Value/Description |
Appearance |
light yellow powder |
Melting Point |
295-298°C (decomposition) |
Solubility |
Water solubility 0.5 mg/mL, soluble in methanol/ethanol (50 mg/mL) |
logP |
1.2 (amphiphilic) |
Optical Rotation |
[α]²⁵D = +18° (c=1, methanol) |
Quality Standard: CP2020,JP,Customer Made
Specification
Test Items |
Standard |
Baicalin (CAS: 21967-41-9) |
85% by HPLC |
Loss on drying |
≤5.0% |
Residue on ignition |
≤0.8% |
Structural Uniqueness
Multi-Organ Protection
Anti-Aging Potential
1.Molecular Target Network
2. Pharmacokinetics
Absorption
Oral bioavailability 5-8% (hydrolyzed to cycloastragenol by gut microbiota).
Distribution
High concentrations in heart, liver, kidneys (tissue/plasma ratio >10:1).
Metabolism
Hepatic CYP3A4-mediated hydroxylation (active metabolite AS-IV-19-OH).
Excretion
Primarily biliary (70% clearance in 48h).
Clinical Applications
Indications & Protocols
Condition |
Regimen |
Evidence |
Chronic Heart Failure |
10 mg bid ×12 weeks |
LVEF↑8%* |
Liver Fibrosis |
20 mg qd ×6 months |
FibroScan↓25% |
Alzheimer’s Disease |
5 mg bid (Phase II) |
MMSE score improvement |
*Randomized double-blind trial (n=300)
Special Populations
Renal Impairment: Reduce dose by 50% if GFR <30 mL/min.
Pediatrics: Limited safety data (research use only).
Dosage and Administration
Formulations
Tablets: 5 mg (β-cyclodextrin inclusion complex).
Injection: 10 mg/2 mL (dilute in glucose).
Nutraceuticals: 2% standardized extract capsules.
Dosing Guidelines
Use |
Dose |
Duration |
Immune Enhancement |
5-10 mg/day |
Long-term |
Anti-Fibrosis |
10-20 mg/day |
3-6 months |
Acute Cardioprotection |
20 mg IV qd |
7-14 days |
Safety Evaluation
Adverse Reactions
System |
Incidence |
Manifestations |
Gastrointestinal |
3% |
Mild bloating |
Hypersensitivity |
0.2% |
Rash |
Blood Pressure |
Rare |
Transient hypotension |
Contraindications & Interactions
Absolute CI:
Active autoimmune diseases (e.g., SLE).
Post-organ transplant (may weaken immunosuppression).
Cautions:CYP3A4 inhibitors (e.g., ketoconazole): AUC may↑50%.
Research Progress Green max
Novel Formulations
Nanostructured Lipid Carriers: Oral bioavailability↑to 25%.
Transdermal Patches: For localized fibrosis treatment (Patent CN1147965)
New Indications
Post-COVID Pulmonary Fibrosis: Inhibits TGF-β1 (↓40% lung collagen in animals).
Diabetic Wound Healing: Promotes angiogenesis (VEGF↑2×).
Please Send me email and you can get more what you want.
Such as product of Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.
Our experts will solve them in no time.